Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.
Robert A HauserHadas BarkayHubert H FernandezJoohi Jimenez-ShahedStewart A FactorNicholas GrossLeslie MarinelliMark Forrest GordonSteve BarashStacy FinkbeinerNayla ChaijaleKaren E AndersonPublished in: Journal of clinical psychopharmacology (2024)
Long-term deutetrabenazine provided clinically meaningful improvements in TD-related movements, with a favorable benefit-risk profile, regardless of underlying condition or DRA use.